A deal to support the development of pioneering cancer treatments has been signed at a major biotech event in San Diego.
At Bio 2017 (BIO International Convention), held last month, a Memorandum of Understanding was agreed between Well Marker Bio – the first ever biotech division of Asan Medical Center of South Korea, CZ Biomed and Kocal Consulting Corporation. The three will collaborate to advance innovative cancer treatments.
CEO of CZ Biomed Corporation, Calvin Cao said: “Signing of this agreement is monumental. Asan Medical Center is aggressively seeking new and innovative ways to advance their treatment of diseases. We look forward to working with them to develop the most effective cancer treatment.”
Well Marker Bio “sees the technological and market potential” of CZ Biomed’s RVLYSIS® cancer treatment, according to Andrew Lim, CEO of Kocal Consulting Corporation.
He added: “In 2013, a stage 4 colon cancer patient received 48 doses of RVLYSIS®. That patient is now living a healthy, active, cancer-free lifestyle. We are extremely excited to be working with Well Marker Bio and the vast resources of Asan Medical Center, the largest medical institution in South Korea. We are one step closer to licensing and commercializing CZ Biomed’s high-tech biological products for the treatment of various cancers.”
